Adverum Biotechnlgs (ADVM) 4.20 $ADVM Can The U
Post# of 273249
Posted On: 09/26/2016 5:16:37 AM
Adverum Biotechnlgs (ADVM) 4.20 $ADVM
Can The Uptrend Continue for Adverum Biotechnologies (ADVM)?
Zacks Equity Research - Zacks Investment Research - Fri Sep 23, 9:32AM CDT
Investors certainly have to be happy with Adverum Biotechnologies Inc (ADVM) and its short term performance
ADVM: 4.20 (+0.01)
Adverum Biotechnologies Presents Preclinical Data on Novel Gene Therapy Candidates for the Treatment of Wet AMD at The Retina Society 2016 Annual Meeting
GlobeNewswire - Fri Sep 16, 6:05AM CDT
Adverum Biotechnologies, Inc. (Nasdaq:ADVM) a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today will present preclinical efficacy data on two new gene therapy candidates, ADVM-022 and ADVM-032, both of which utilize a novel vector designed to allow for intravitreal rather than the more invasive surgical subretinal delivery to potentially treat wet AMD (wAMD) as well as other retinal conditions associated with VEGF over-expression. These results will be presented today at The Retina Society 2016 Annual Meeting in San Diego by the Chairman of the Board of Directors of Adverum, Dr. Mark Blumenkranz, who is also HJ Smead Professor in the Department of Ophthalmology at Stanford University.
ADVM: 4.20 (+0.01)
Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 8:31AM CDT
Adverum (ADVM) reported a narrower-than-expected loss in the second quarter. The company also decided to discontinue the development of lead candidate.
ADVM: 4.20 (+0.01), CORT: 6.49 (unch), PCRX: 36.86 (-0.66), REGN: 410.39 (+2.38)
Adverum Biotechnologies, Inc. Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:05PM CDT
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today reported financial results for the quarter ended June 30, 2016.
ADVM: 4.20 (+0.01)
Adverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye
GlobeNewswire - Tue Aug 09, 6:05AM CDT
-Collaboration Brings Together Vector and Ophthalmology Expertise of Adverum with Genome Editing Capabilities of Editas-
ADVM: 4.20 (+0.01), EDIT: 14.46 (-0.34)
What's in Store for Adverum (ADVM) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:47AM CDT
Adverum Biotechnologies, Inc. (ADVM) is expected to report second-quarter 2016 results on Aug 11.
ADVM: 4.20 (+0.01), ADHD: 4.65 (-0.05), AVXS: 41.43 (-1.07), REGN: 410.39 (+2.38)
Adverum Biotechnologies Appoints Leone Patterson as Chief Financial Officer
PR Newswire - Mon Jun 13, 7:32AM CDT
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) a gene therapy company committed to discovering and developing novel medicines for patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options, today announced the appointment of Leone Patterson as chief financial officer (CFO). Ms. Patterson brings more than 20 years of professional finance and accounting experience to Adverum.
ADVM: 4.20 (+0.01)
Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies
GlobeNewswire - Thu May 12, 6:00AM CDT
--New Trading Symbol (NASDAQ:ADVM) Effective May 12, 2016--
ADVM: 4.20 (+0.01), AAVL: 4.14 (-0.18)
Can The Uptrend Continue for Adverum Biotechnologies (ADVM)?
Zacks Equity Research - Zacks Investment Research - Fri Sep 23, 9:32AM CDT
Investors certainly have to be happy with Adverum Biotechnologies Inc (ADVM) and its short term performance
ADVM: 4.20 (+0.01)
Adverum Biotechnologies Presents Preclinical Data on Novel Gene Therapy Candidates for the Treatment of Wet AMD at The Retina Society 2016 Annual Meeting
GlobeNewswire - Fri Sep 16, 6:05AM CDT
Adverum Biotechnologies, Inc. (Nasdaq:ADVM) a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today will present preclinical efficacy data on two new gene therapy candidates, ADVM-022 and ADVM-032, both of which utilize a novel vector designed to allow for intravitreal rather than the more invasive surgical subretinal delivery to potentially treat wet AMD (wAMD) as well as other retinal conditions associated with VEGF over-expression. These results will be presented today at The Retina Society 2016 Annual Meeting in San Diego by the Chairman of the Board of Directors of Adverum, Dr. Mark Blumenkranz, who is also HJ Smead Professor in the Department of Ophthalmology at Stanford University.
ADVM: 4.20 (+0.01)
Adverum (ADVM) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 8:31AM CDT
Adverum (ADVM) reported a narrower-than-expected loss in the second quarter. The company also decided to discontinue the development of lead candidate.
ADVM: 4.20 (+0.01), CORT: 6.49 (unch), PCRX: 36.86 (-0.66), REGN: 410.39 (+2.38)
Adverum Biotechnologies, Inc. Reports Second Quarter 2016 Financial Results
GlobeNewswire - Tue Aug 09, 3:05PM CDT
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today reported financial results for the quarter ended June 30, 2016.
ADVM: 4.20 (+0.01)
Adverum Biotechnologies and Editas Medicine Announce Collaboration to Explore Delivery of Genome Editing Medicines to the Eye
GlobeNewswire - Tue Aug 09, 6:05AM CDT
-Collaboration Brings Together Vector and Ophthalmology Expertise of Adverum with Genome Editing Capabilities of Editas-
ADVM: 4.20 (+0.01), EDIT: 14.46 (-0.34)
What's in Store for Adverum (ADVM) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 9:47AM CDT
Adverum Biotechnologies, Inc. (ADVM) is expected to report second-quarter 2016 results on Aug 11.
ADVM: 4.20 (+0.01), ADHD: 4.65 (-0.05), AVXS: 41.43 (-1.07), REGN: 410.39 (+2.38)
Adverum Biotechnologies Appoints Leone Patterson as Chief Financial Officer
PR Newswire - Mon Jun 13, 7:32AM CDT
Adverum Biotechnologies, Inc. (NASDAQ: ADVM) a gene therapy company committed to discovering and developing novel medicines for patients living with rare diseases or diseases of the eye who currently have limited or burdensome treatment options, today announced the appointment of Leone Patterson as chief financial officer (CFO). Ms. Patterson brings more than 20 years of professional finance and accounting experience to Adverum.
ADVM: 4.20 (+0.01)
Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics and Changes Name to Adverum Biotechnologies
GlobeNewswire - Thu May 12, 6:00AM CDT
--New Trading Symbol (NASDAQ:ADVM) Effective May 12, 2016--
ADVM: 4.20 (+0.01), AAVL: 4.14 (-0.18)
(0)
(0)Scroll down for more posts ▼